These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11114281)

  • 21. Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: transient 'seronegative' antiphospholipid syndrome?
    Miret C; Cervera R; Reverter JC; García-Carrasco M; Ramos M; Mollà M; Font J; Ingelmo M
    Clin Exp Rheumatol; 1997; 15(5):541-4. PubMed ID: 9307863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticardiolipin antibodies in childhood rheumatic disorders.
    Gedalia A; Molina JF; García CO; Doggett S; Espinoza LR; Gharavi AE
    Lupus; 1998; 7(8):551-3. PubMed ID: 9863898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticardiolipin antibodies and clinical spectrum of antiphospholipid syndrome in patients with systemic lupus erythematosus.
    Petrović R; Petrović M; Novicić-Sasić D; Cirović L; Damjanov N; Palić D
    Vojnosanit Pregl; 1998; 55(2 Suppl):23-8. PubMed ID: 9623355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome.
    Fanopoulos D; Teodorescu MR; Varga J; Teodorescu M
    J Rheumatol; 1998 Apr; 25(4):675-80. PubMed ID: 9558168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies to beta2-glycoprotein-I: relation of anticardiolipin antibodies with clinical and laboratory parameters in patients with systemic lupus erythematosus.
    Sahin M; Duzgun N; Tunc SE; Tutkak H
    Clin Biochem; 2007 May; 40(8):526-30. PubMed ID: 17359958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population].
    Marai I; Levi Y; Godard G; Shoenfeld Y
    Harefuah; 2001 Jun; 140(6):495-500, 565. PubMed ID: 11420848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.
    Cabiedes J; Cabral AR; Alarcón-Segovia D
    J Rheumatol; 1995 Oct; 22(10):1899-906. PubMed ID: 8991989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diastolic dysfunction is a feature of the antiphospholipid syndrome.
    Hasnie AM; Stoddard MF; Gleason CB; Wagner SG; Longaker RA; Pierangeli S; Harris EN
    Am Heart J; 1995 May; 129(5):1009-13. PubMed ID: 7732958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients.
    López-Soto A; Cervera R; Font J; Bové A; Reverter JC; Muñoz FJ; Miret C; Espinosa G; Ordinas A; Ingelmo M
    Clin Exp Rheumatol; 1997; 15(2):143-9. PubMed ID: 9196865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined search for anti-beta2-glycoprotein I and anticardiolipin antibodies in antiphospholipid syndrome: contribution to diagnosis.
    Sanmarco M; Roll P; Gayet S; Oksman F; Johanet C; Escande A; Cohen JH; Chevailler A; Goetz J; Humbel RL; Sibilia J
    J Lab Clin Med; 2004 Sep; 144(3):141-7. PubMed ID: 15454883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-lysobisphosphatidic acid antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus.
    Alessandri C; Bombardieri M; Di Prospero L; Conigliaro P; Conti F; Labbadia G; Misasi R; Sorice M; Valesini G
    Clin Exp Immunol; 2005 Apr; 140(1):173-80. PubMed ID: 15762889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BF*F allotype of the alternative pathway of complement: A marker of protection against the development of antiphospholipid antibodies in patients with systemic lupus erythematosus.
    Picceli VF; Skare TL; Nisihara RM; Nass FR; Messias-Reason IT; Utiyama SR
    Lupus; 2016 Apr; 25(4):412-7. PubMed ID: 26537423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
    Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
    J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome.
    von Scheven E; Glidden DV; Elder ME
    Arthritis Rheum; 2002 Aug; 47(4):414-20. PubMed ID: 12209489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study.
    Vlachoyiannopoulos PG; Kanellopoulos PG; Ioannidis JP; Tektonidou MG; Mastorakou I; Moutsopoulos HM
    Rheumatology (Oxford); 2003 May; 42(5):645-51. PubMed ID: 12709540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus.
    Szodoray P; Tarr T; Tumpek J; Kappelmayer J; Lakos G; Poor G; Szegedi G; Kiss E
    Autoimmunity; 2009 Sep; 42(6):497-506. PubMed ID: 19626489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome].
    Sarzi-Puttini P; Atzeni F; Carrabba M
    Minerva Med; 2003 Apr; 94(2):63-70. PubMed ID: 12858154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ocular manifestations in patients with systemic lupus erythematosus and antiphospholipid syndrome].
    Ostanek L; Modrzejewska M; Bobrowska-Snarska D; Brzosko M
    Pol Arch Med Wewn; 2007; 117 Suppl():18-23. PubMed ID: 18778014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prevalence of anticardiolipin antibody in patients with systemic lupus erythematosus and its association with clinical manifestations.
    Basiri Z; Gholyaf M; Faridnia M; Nadi E; Bairanvand M
    Acta Med Iran; 2013; 51(1):35-40. PubMed ID: 23456582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.